Vista Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
10.34 -0.35 (-3.27%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
10.16
Today’s High
10.78
52 Week Low
9.10
52 Week High
16.59
Key Metrics
- Market Cap (In Cr) 63.35
- Beta -0.32
- Div. Yield (%) 0
- P/B 0.28
- TTM P/E -
- Sector P/E 22.43
- D/E 0
- Open Price 10.2
- Prev Close 10.69
Vista Pharmaceuticals Analysis
Price Analysis
-
1 Week-2.26%
-
3 Months-3.17%
-
6 Month-10.11%
-
YTD-11.71%
-
1 Year-17.53%
Risk Meter
- 46% Low risk
- 46% Moderate risk
- 46% Balanced Risk
- 46% High risk
- 46% Extreme risk
Vista Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 10.07
- Selling/ General/ Admin Expenses Total
- 2
- Depreciation/ Amortization
- 0.74
- Other Operating Expenses Total
- 3.75
- Total Operating Expense
- 14.84
- Operating Income
- -4.77
- Net Income Before Taxes
- -5.29
- Net Income
- -4.65
- Diluted Normalized EPS
- -0.79
- Period
- 2025
- Total Assets
- 60.29
- Total Liabilities
- 14.87
- Total Equity
- 45.42
- Tangible Book Valueper Share Common Eq
- 29.14
- Period
- 2025
- Cashfrom Operating Activities
- -6.98
- Cashfrom Investing Activities
- -0.44
- Cashfrom Financing Activities
- 8.06
- Net Changein Cash
- 0.64
- Period
- 2024
- Total Revenue
- 10.29
- Selling/ General/ Admin Expenses Total
- 1.79
- Depreciation/ Amortization
- 0.72
- Other Operating Expenses Total
- 3.17
- Total Operating Expense
- 14.58
- Operating Income
- -4.29
- Net Income Before Taxes
- -5.18
- Net Income
- -4.51
- Diluted Normalized EPS
- -1.03
- Period
- 2024
- Total Assets
- 57.98
- Total Liabilities
- 17.52
- Total Equity
- 40.46
- Tangible Book Valueper Share Common Eq
- 6.55
- Period
- 2024
- Cashfrom Operating Activities
- -4.91
- Cashfrom Investing Activities
- -0.79
- Cashfrom Financing Activities
- 5.59
- Net Changein Cash
- -0.11
- Period
- 2023
- Total Revenue
- 1
- Selling/ General/ Admin Expenses Total
- 0.51
- Depreciation/ Amortization
- 0.62
- Other Operating Expenses Total
- 2.11
- Total Operating Expense
- 6.07
- Operating Income
- -5.06
- Net Income Before Taxes
- -5.88
- Net Income
- -5.66
- Diluted Normalized EPS
- -1.54
- Period
- 2023
- Total Assets
- 56.03
- Total Liabilities
- 19.32
- Total Equity
- 36.71
- Tangible Book Valueper Share Common Eq
- 7.23
- Period
- 2023
- Cashfrom Operating Activities
- -1.71
- Cashfrom Investing Activities
- -1.27
- Cashfrom Financing Activities
- 3.11
- Net Changein Cash
- 0.13
- Period
- 2022
- Total Revenue
- 0.39
- Selling/ General/ Admin Expenses Total
- 0.57
- Depreciation/ Amortization
- 0.62
- Other Operating Expenses Total
- 0.66
- Total Operating Expense
- 2.22
- Operating Income
- -1.83
- Net Income Before Taxes
- -2.56
- Net Income
- -0.83
- Diluted Normalized EPS
- -0.23
- Period
- 2022
- Total Assets
- 55.59
- Total Liabilities
- 20.14
- Total Equity
- 35.45
- Tangible Book Valueper Share Common Eq
- 7.04
- Period
- 2022
- Cashfrom Operating Activities
- -0.99
- Cashfrom Investing Activities
- -0.01
- Cashfrom Financing Activities
- 0.94
- Net Changein Cash
- -0.07
- Period
- 2021
- Total Revenue
- 1.27
- Selling/ General/ Admin Expenses Total
- 1.15
- Depreciation/ Amortization
- 0.73
- Other Operating Expenses Total
- 1.11
- Total Operating Expense
- 3.72
- Operating Income
- -2.46
- Net Income Before Taxes
- -3.69
- Net Income
- -1.89
- Diluted Normalized EPS
- -0.54
- Period
- 2021
- Total Assets
- 50.85
- Total Liabilities
- 18.01
- Total Equity
- 32.85
- Tangible Book Valueper Share Common Eq
- 6.33
- Period
- 2021
- Cashfrom Operating Activities
- -6.75
- Cashfrom Investing Activities
- -0.3
- Cashfrom Financing Activities
- 6.96
- Net Changein Cash
- -0.09
- Period
- 2020
- Total Revenue
- 22.76
- Selling/ General/ Admin Expenses Total
- 1.48
- Depreciation/ Amortization
- 1.35
- Other Operating Expenses Total
- 2.13
- Total Operating Expense
- 28.9
- Operating Income
- -6.14
- Net Income Before Taxes
- -3.94
- Net Income
- -3.68
- Diluted Normalized EPS
- -1.21
- Period
- 2020
- Total Assets
- 51.12
- Total Liabilities
- 21.48
- Total Equity
- 29.64
- Tangible Book Valueper Share Common Eq
- 6.62
- Period
- 2020
- Cashfrom Operating Activities
- 0.8
- Cashfrom Investing Activities
- -1.73
- Cashfrom Financing Activities
- 0.28
- Net Changein Cash
- -0.64
- Period
- 2019
- Total Revenue
- 31.07
- Selling/ General/ Admin Expenses Total
- 1.36
- Depreciation/ Amortization
- 1.36
- Other Operating Expenses Total
- 3.06
- Total Operating Expense
- 31.2
- Operating Income
- -0.13
- Net Income Before Taxes
- 1.15
- Net Income
- 0.94
- Diluted Normalized EPS
- 0.3
- Period
- 2019
- Total Assets
- 52.76
- Total Liabilities
- 16.96
- Total Equity
- 35.8
- Tangible Book Valueper Share Common Eq
- 9.13
- Period
- 2019
- Cashfrom Operating Activities
- 3.3
- Cashfrom Investing Activities
- -5.65
- Cashfrom Financing Activities
- 1.43
- Net Changein Cash
- -0.92
- Period
- 2025-03-31
- Total Revenue
- 3.23
- Selling/ General/ Admin Expenses Total
- 0.56
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.89
- Total Operating Expense
- 4.33
- Operating Income
- -1.1
- Net Income Before Taxes
- -1.06
- Net Income
- -1.5
- Diluted Normalized EPS
- -0.79
- Period
- 2025-03-31
- Total Assets
- 60.29
- Total Liabilities
- 14.87
- Total Equity
- 45.42
- Tangible Book Valueper Share Common Eq
- 29.14
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -6.98
- Cashfrom Investing Activities
- -0.44
- Cashfrom Financing Activities
- 8.06
- Net Changein Cash
- 0.64
- Period
- 2024-12-31
- Total Revenue
- 2.56
- Selling/ General/ Admin Expenses Total
- 0.52
- Depreciation/ Amortization
- 0.19
- Other Operating Expenses Total
- 1.06
- Total Operating Expense
- 4.26
- Operating Income
- -1.7
- Net Income Before Taxes
- -1.8
- Net Income
- -1.32
- Diluted Normalized EPS
- -0.21
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2.49
- Selling/ General/ Admin Expenses Total
- 0.48
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 1.29
- Total Operating Expense
- 3.5
- Operating Income
- -1.01
- Net Income Before Taxes
- -1.25
- Net Income
- -0.97
- Diluted Normalized EPS
- -0.16
- Period
- 2024-09-30
- Total Assets
- 63.64
- Total Liabilities
- 15.41
- Total Equity
- 48.23
- Tangible Book Valueper Share Common Eq
- 6.28
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -5.15
- Cashfrom Investing Activities
- -0.25
- Cashfrom Financing Activities
- 7.94
- Net Changein Cash
- 2.54
- Period
- 2024-06-30
- Total Revenue
- 1.8
- Selling/ General/ Admin Expenses Total
- 0.45
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.52
- Total Operating Expense
- 2.75
- Operating Income
- -0.96
- Net Income Before Taxes
- -1.17
- Net Income
- -0.86
- Diluted Normalized EPS
- -0.15
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3.13
- Selling/ General/ Admin Expenses Total
- 0.48
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.89
- Total Operating Expense
- 3.05
- Operating Income
- 0.08
- Net Income Before Taxes
- -0.1
- Net Income
- 0.09
- Diluted Normalized EPS
- 0.02
- Period
- 2024-03-31
- Total Assets
- 57.98
- Total Liabilities
- 17.52
- Total Equity
- 40.46
- Tangible Book Valueper Share Common Eq
- 6.55
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -4.91
- Cashfrom Investing Activities
- -0.79
- Cashfrom Financing Activities
- 5.59
- Net Changein Cash
- -0.11
- Period
- 2023-12-31
- Total Revenue
- 1.7
- Selling/ General/ Admin Expenses Total
- 0.45
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.78
- Total Operating Expense
- 3.63
- Operating Income
- -1.93
- Net Income Before Taxes
- -2.2
- Net Income
- -1.63
- Diluted Normalized EPS
- -0.33
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Vista Pharmaceuticals Technical
Moving Average
SMA
- 5 Day10.35
- 10 Day10.66
- 20 Day10.89
- 50 Day10.9
- 100 Day10.84
- 300 Day11.49
Vista Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Godavari Drugs
- 93
- -0.37
- -0.4
- 155
- 79
- 70.16
- Vasundhara Rasayans
- 209.3
- 4.05
- 1.97
- 398
- 185.05
- 66.6
- Vista Pharmaceuticals
- 10.34
- -0.35
- -3.27
- 16.59
- 9.1
- 63.35
- Jeevan Scientific Technology
- 39.39
- 0.9
- 2.34
- 67.8
- 36.5
- 62.36
- Lasa Supergenerics
- 10.29
- 0.49
- 5
- 33.49
- 8.52
- 51.55
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Godavari Drugs
- 15.96
- 1.61
- 14.59
- 3.24
- Vasundhara Rasayans
- 15.28
- 1.83
- 16.43
- 13.14
- Vista Pharmaceuticals
- -
- 0.28
- -9.58
- -76.17
- Jeevan Scientific Technology
- 984.75
- 1.25
- 9.04
- 8.68
- Lasa Supergenerics
- -
- 0.61
- -8.95
- -8.05
Vista Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results
- 19-Feb-25
- Preferential Issue of shares & Others
- 12-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 28-May-24
- Audited Results
- 10-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 20-Mar-25
- 25-Feb-25
- EGM
- 30-Sept-24
- 19-Sept-24
- AGM
- 30-Sept-23
- 06-Sept-23
- AGM
- 29-Sept-22
- 13-Aug-22
- AGM
- 25-Sept-21
- 14-Aug-21
- AGM
- 29-Dec-20
- 12-Nov-20
- AGM



